3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Interventions
Cyclophosphamide
28
Temozolomide
25
Irinotecan
21
dinutuximab
20
Topotecan
15
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Biopsy
12
naxitamab
11
Granulocyte-Macrophage Colony-Stimulating Factor
11
3-Iodobenzylguanidine
11
Vincristine
10
Etoposide
10
sargramostim
9
Melphalan
9
Isotretinoin
9
fludarabine
8
X-Rays
8
Colony-Stimulating Factors
8
Carboplatin
8
etoposide phosphate
7
Phantoms, Imaging
7
Doxorubicin
7
fludarabine phosphate
6
Stem Cell Transplantation
6
Nuclear Medicine Department, Hospital
6
Eflornithine
6
Thiotepa
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
CLR1404
×
1 year
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled